News Releases

Date	Title and Summary	View
Jan 22, 2019	Johnson & Johnson Reports 2018 Fourth-Quarter Results: 2018 Fourth-Quarter Sales of $20.4 Billion increased 1.0%; EPS was $1.12 2018 Full-Year Sales of $81.6 Billion increased 6.7%, Full-Year EPS was $5.61 Adjusted 2018 Fourth-Quarter EPS was $1.97, an increase of 13.2%, and Adjusted 2018 Full-Year EPS was $8.18, an increase of 12.1% Strong 2018
Jan 17, 2019	Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention Johnson & Johnson to collaborate with Apple to assess impact of wearable technology on earlier detection of AFib, improved diagnosis and patient outcomes Up to 30 percent of AFib cases go undiagnosed until life-threatening complications occur, signaling a critical need for more efficient and
Jan 15, 2019	Janssen announces European Commission approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease
Jan 11, 2019	Johnson & Johnson Recommends Rejection Of Below-Market "Mini-Tender" Offer By Peer & Peri LLC NEW BRUNSWICK, N.J. , Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) received notice of an unsolicited "mini-tender" offer by Peer & Peri LLC (Peer & Peri) to purchase up to 30,000 shares of common stock of Johnson & Johnson , representing approximately 0.001% of the company's
Jan 11, 2019	Johnson & Johnson Announces completion of Offer for Ci:z Holdings Co., Ltd. NEW BRUNSWICK, N.J. , Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the conditions to its public tender offer for all of the outstanding shares of Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company") not already held by Johnson & Johnson or its affiliates that was
Jan 07, 2019	Janssen Submits Application to European Medicines Agency Seeking Approval of STELARA® (USTEKINUMAB) for Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
Jan 02, 2019	Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019 NEW BRUNSWICK, N.J. , Jan. 2, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2019 of $0.90 per share on the company's common stock. The dividend is payable on March 12, 2019 to shareholders of
Dec 24, 2018	Johnson & Johnson to Participate in 37th Annual JP Morgan Health Care Conference NEW BRUNSWICK, N.J. , Dec. 24, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 37 th Annual JP Morgan Health Care Conference on Monday, Jan. 7 th , at the Westin St. Francis in San Francisco. Joseph J. Wolk , Executive Vice President and Chief Financial Officer; Jennifer
Dec 20, 2018	Janssen Submits Application to U.S. FDA Seeking Approval of STELARA® (USTEKINUMAB) for Treatment of Moderately to Severely Active Ulcerative Colitis
Dec 19, 2018	Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results NEW BRUNSWICK, N.J. , Dec. 19, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 22 nd , to review fourth-quarter results. Alex Gorsky , Chairman and Chief Executive Officer; Joseph J.